161 related articles for article (PubMed ID: 3124306)
1. Effect of virucidal heat treatment on proteins in human factor VIII concentrates.
Thomas KB; McGrath KM; Taylor M; Young IF; Herrington RW; Schiff P
Transfusion; 1988; 28(1):8-13. PubMed ID: 3124306
[TBL] [Abstract][Full Text] [Related]
2. Characteristics of the von Willebrand factor in virus inactivated F VIII concentrates: the impact of heat treatment.
Ingerslev J; Bukh A; Wallevik K; Møller NP; Stenbjerg S
Thromb Res; 1987 Jul; 47(2):175-82. PubMed ID: 3116714
[TBL] [Abstract][Full Text] [Related]
3. [Study of a therapeutic concentrate of factor VIII/vWf prepared in a closed system].
Mazurier C; Maillard J; Parquet-Gernez A; Goudemand M
Rev Fr Transfus Immunohematol; 1982 Feb; 25(1):25-43. PubMed ID: 6803339
[TBL] [Abstract][Full Text] [Related]
4. In vitro characterization of various factor VIII concentrates.
Yoshioka A; Shima M; Nishino M; Yoshikawa N; Fukui H
Arzneimittelforschung; 1987 Jul; 37(7):753-6. PubMed ID: 3118888
[TBL] [Abstract][Full Text] [Related]
5. Cryoprecipitate and Factor VIII commercial concentrates: in vitro characteristics and in vivo compartmental analysis.
Morfini M; Longo G; Matucci M; Vannini S; Messori A; Filimberti E; Duminuco M; Avanzi G; Rossi-Ferrini P
Ric Clin Lab; 1984; 14(4):681-91. PubMed ID: 6441235
[TBL] [Abstract][Full Text] [Related]
6. Proteomic characterization of plasma-derived clotting factor VIII-von Willebrand factor concentrates.
Clifton JG; Huang F; Kovac S; Yang X; Hixson DC; Josic D
Electrophoresis; 2009 Oct; 30(20):3636-46. PubMed ID: 19768705
[TBL] [Abstract][Full Text] [Related]
7. Multimers of von Willebrand antigen in therapeutic factor VIII concentrates.
Vukovich TC
Folia Haematol Int Mag Klin Morphol Blutforsch; 1986; 113(6):831-40. PubMed ID: 2436998
[TBL] [Abstract][Full Text] [Related]
8. Use of heat-treated clotting-factor concentrates in patients with haemophilia and a high exposure to HTLV-III.
McGrath KM; Thomas KB; Herrington RW; Turner PJ; Taylor L; Ekert H; Schiff P; Gust ID
Med J Aust; 1985 Jul; 143(1):11-3. PubMed ID: 2989666
[TBL] [Abstract][Full Text] [Related]
9. Von Willebrand factor multimers in virus-inactivated plasmas and F VIII concentrates.
Budde U; Drewke E
Beitr Infusionsther Transfusionsmed; 1994; 32():408-14. PubMed ID: 9422121
[TBL] [Abstract][Full Text] [Related]
10. Influence of dry heat treatment and anticoagulant on coupling of fibrinogen and fibronectin to von Willebrand factor in normal plasma.
Ellegård KH; Christiansen K; Ingerslev J
Scand J Clin Lab Invest; 1992 Nov; 52(7):731-9. PubMed ID: 1333636
[TBL] [Abstract][Full Text] [Related]
11. Protein content and factor VIII complex in untreated, treated and monoclonal factor VIII concentrates.
Morfini M; Rafanelli D; Filimberti E; Cinotti S; Piazza E; Longo G; Rossi Ferrini P
Thromb Res; 1989 Oct; 56(2):169-78. PubMed ID: 2515605
[TBL] [Abstract][Full Text] [Related]
12. An electroblotting technique for the detection of factor VIII/von Willebrand factor multimers in plasma.
Furlong BL; Peake IR
Br J Haematol; 1983 Apr; 53(4):641-53. PubMed ID: 6403025
[TBL] [Abstract][Full Text] [Related]
13. Development of a heat-treated factor VIII/von Willebrand factor concentrate prepared from heparinized plasma.
Palmer DS; Ganz PR; Perkins H; Rosborough D; Rock G
Thromb Haemost; 1990 Jun; 63(3):392-402. PubMed ID: 2119525
[TBL] [Abstract][Full Text] [Related]
14. Variant von Willebrand's disease: characterization of two subtypes by analysis of multimeric composition of factor VIII/von Willebrand factor in plasma and platelets.
Ruggeri ZM; Zimmerman TS
J Clin Invest; 1980 Jun; 65(6):1318-25. PubMed ID: 6773982
[TBL] [Abstract][Full Text] [Related]
15. A critical evaluation of the available methods for the determination of factor VIII von Willebrand.
Casonato A; Girolami A
Folia Haematol Int Mag Klin Morphol Blutforsch; 1986; 113(5):670-84. PubMed ID: 2435633
[TBL] [Abstract][Full Text] [Related]
16. Biochemical and in vivo properties of commercial virus-inactivated factor VIII concentrates.
Berntorp E; Nilsson IM
Eur J Haematol; 1988 Mar; 40(3):205-14. PubMed ID: 3128452
[TBL] [Abstract][Full Text] [Related]
17. [Properties of factor VIII/von Willebrand factor in two highly-purified factor VIII concentrates, Hemofil M and Monoclate, using monoclonal antibodies].
Tanaka I; Yoshioka A; Shima M; Fujiwara T; Terada S; Nakai H; Miyata S; Sawamoto Y; Kamisue S; Fukui H
Rinsho Ketsueki; 1989 Jul; 30(7):951-7. PubMed ID: 2509762
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the in vitro characteristics of von Willebrand factor in British and commercial factor VIII concentrates.
Lawrie AS; Harrison P; Armstrong AL; Wilbourn BR; Dalton RG; Savidge GF
Br J Haematol; 1989 Sep; 73(1):100-4. PubMed ID: 2508742
[TBL] [Abstract][Full Text] [Related]
19. Double cryoprecipitated factor VIII concentrate from heparinised plasma and its heat treatment.
Smit Sibinga CT; Schulting PJ; Notebomer J; Das PC; Marrink J; vd Meer J
Blut; 1988 Mar; 56(3):111-6. PubMed ID: 3128351
[TBL] [Abstract][Full Text] [Related]
20. von Willebrand factor characterization of a severe dry-heat treated factor VIII concentrate, AHF (high purity).
Oates A; Polmear E; Herrington R; Farrugia A; Sykes S; Raines G; Aumann H; Street A
Thromb Res; 1992 Feb; 65(3):389-99. PubMed ID: 1631803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
